News Search Results
Aug 14, 2025, 05:24 ET Leads Biolabs Announces Completion of Patient Enrollment in Pivotal Trial of Opamtistomig Monotherapy for Extrapulmonary Neuroendocrine Carcinoma
the urgency to develop novel therapeutic approaches. About Leads Biolabs Founded in 2012, Leads Biolabs is a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of innovative therapies to address underserved medical needs in oncology,
More news about: Leads Biolabs
Aug 13, 2025, 16:00 ET Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2025 Financial Results
https://clinicaltrials.gov/study/ NCT06996080). About Kodiak Sciences Inc. Kodiak Sciences (Nasdaq: KOD) is a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics. We are focused on bringing new science to the design
More news about: Kodiak Sciences Inc.
Aug 13, 2025, 11:50 ET WallachBeth Capital Announces Pricing of bioAffinity Technologies Private Placement and Concurrent Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds
bioAffinity Technologies, Inc. (NASDAQ: BIAF and BIAFW) ) a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer has entered into securities purchase agreements with several
More news about: WallachBeth Capital LLC
Aug 13, 2025, 08:34 ET Chungnam National University Researchers Develop Next-Gen Zinc Batteries: Artificial Polymer Nanolayers Improve Zinc Battery Stability
university with a strong focus on research and education. Thanks to its location near the Daedeok Innopolis R&D hub, it excels in fields such as biotechnology, materials science, and information technology. About Associate Professor Woo-Jin Song Dr. Woo-Jin
More news about: Chungnam National University
Aug 13, 2025, 08:27 ET CIT Therapeutics Forms Strategic Partnership with the Institute for Follicular Lymphoma Innovation (IFLI), Securing Up to $2.5M to Advance Novel Cancer Therapies
Calif., Aug. 13, 2025 /PRNewswire/ -- CIT Therapeutics, Inc. (CIT), a biotechnology company focused on developing next-generation small molecule therapies targeting SUMOylation for cancer treatment, today announced a strategic partnership
More news about: Institute for Follicular Lymphoma Innovation (IFLI); CIT Therapeutics, Inc.
Aug 13, 2025, 08:05 ET TetraScience Launches Tetra Workflows to Automate Scientific Data Workflows at Scale
Modern laboratories are drowning in data management complexity. Scientists across pharmaceutical, biotechnology, and life sciences organizations waste up to 40% of their time on manual data movement between instruments, electronic lab notebooks (ELNs), laboratory
More news about: TetraScience
Aug 13, 2025, 08:00 ET Apertura Gene Therapy Licenses Blood-Brain Barrier-Penetrant AAV Capsid to Multiple Partners Advancing Central Nervous System Treatments
NEW YORK, Aug. 13, 2025 /PRNewswire/ -- Apertura Gene Therapy, a biotechnology company focused on innovative gene therapy solutions announced several licensing deals with Galibra Neuroscience and Emugen Therapeutics to utilize
More news about: Apertura Gene Therapy
Aug 13, 2025, 08:00 ET BioDlink Accelerates Global Expansion with Bevacizumab Launch in Colombia and Pakistan
therapeutic fields, builds cutting-edge biotechnology platforms such as new protein, new antibody, nucleic acid drugs, and adheres to the platform driven development model of "innovation+internationalization", At the same time, it explores the extensive application of biotechnology in the field of general health,
More news about: BioDlink Biopharm Co., Ltd.
Aug 12, 2025, 19:57 ET CAPR Stock News: Investors with Large Losses Should Contact Robbins LLP to Learn About Leading the Capricor Therapeutics, Inc. Class Action Lawsuit
securities between October 9, 2024 and July 10, 2025. Capricor is a clinical-stage biotechnology company that engages in the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD) and
More news about: Robbins LLP
Aug 12, 2025, 19:00 ET Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, Demonstrated Greater Efficacy with Tirzepatide than Semaglutide in a Preclinical Model
including tirzepatide in future clinical trials." About Ascletis Pharma Inc. Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics to treat metabolic diseases.
More news about: Ascletis Pharma Inc.
Aug 12, 2025, 18:51 ET REPL Stock News: Investors with Large Losses Should Contact Robbins LLP for Information About Leading the Replimune Group, Inc. Class Action Lawsuit
between November 22, 2024 and July 21, 2025. Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer.
More news about: Robbins LLP
Aug 12, 2025, 17:31 ET Tumor-Infiltrating Lymphocyte Therapy Market Gains Momentum with Expanding Oncology Applications | DelveInsight
TILs, the complex and time-intensive production process. The competitive landscape is becoming increasingly dynamic, with numerous biotechnology firms and academic institutions entering the TIL space. Strategic partnerships, technology licensing, and mergers & acquisitions are
More news about: DelveInsight Business Research, LLP
Aug 12, 2025, 16:05 ET Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update
Aug. 12, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat
More news about: Armata Pharmaceuticals, Inc.
Aug 12, 2025, 16:05 ET INOVIO Reports Second Quarter 2025 Financial Results and Recent Business Highlights
MEETING, Pa., Aug. 12, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious
More news about: INOVIO Pharmaceuticals, Inc.
Aug 12, 2025, 13:12 ET New Study Confirms LP815® Probiotic Reduces Canine Anxiety and Aggression
https://doi.org/10.3390/ani15152280 About Verb BioticsVerb Biotics is a B2B biotechnology company that delivers clinically validated microbiome ingredients to functional food, beverage, dietary supplement, and companion animal brands.
More news about: Verb Biotics
Aug 12, 2025, 11:09 ET Healthcare AI Market Explodes 38.5% Annually as Diagnostics Gain FDA Traction
diseases including diabetes, heart failure, and kidney disease management. Tevogen Bio Holdings Inc. (NASDAQ: TVGN) has evolved from a biotechnology company into a dual-platform enterprise expanding into artificial intelligence through Tevogen.AI while maintaining 74% insider ownership. The company
More news about: USA News Group
Aug 12, 2025, 11:00 ET Gameto's $44M Series C to Help Redefine Reproductive Care, as First Patients Recruited for Pivotal Stem Cell Phase 3 Trial
As birth rates decline and US IVF access falls further behind, Gameto recruits first Phase 3 patients for cutting-edge biotechnology to reignite reproductive health possibilities Company's $127 million in total funding represents one of
More news about: Gameto
Aug 12, 2025, 11:00 ET Mice Model Market worth US$2.74 billion in 2030 with 10.0% CAGR | MarketsandMarkets™
participants. The US is the primary revenue contributor due to the concentration of contract research organizations, academic research centers, and biotechnology firms. Companies such as Charles River Laboratories (US), The Jackson Laboratory (US), and Inotiv (US) operate large-scale breeding and research
More news about: MarketsandMarkets
Aug 12, 2025, 10:01 ET Hearing Aids Market worth US$14.42 billion by 2030 with 6.8% CAGR | MarketsandMarkets™
Japan), Eargo Inc. (US), Starkey Laboratories, Inc. (US), WSAudiology (Denmark), Zhejiang Nurotron Biotechnology Co., Ltd. (China), and MED-EL Medical Electronics (Austria), among others.
More news about: MarketsandMarkets
Aug 12, 2025, 10:00 ET Jocasta Neuroscience Lands $35 Million Series A to Advance Longevity Protein Program for Managing Cognitive Impairment
A. Coulter Endowed Chair in Aging and Neurodegenerative Disease as well, a Cofounder of Jocasta Neurosciences Inc. It was then licensed to Unity Biotechnology, Inc., a publicly traded company based in San Francisco, in 2018. Unity developed Klotho protein for several years
More news about: Jocasta Neurosciences Inc.
Aug 12, 2025, 10:00 ET Former Pfizer Chief Scientific Officer joins MC Sciences as Independent Chairman
remains a globally respected leader in pharmaceutical R&D. About MC Sciences MC Sciences is an emerging biotechnology company developing first-in-class, best-in-category therapeutics that target mast cells across high-need disease indications. The company's scientific
More news about: MC Sciences UG
Aug 12, 2025, 09:16 ET Scout Named to 2025 Inc. 5000 List of Fastest-Growing Private Companies
deliver face-to-face, virtual, and hybrid clinical meeting planning, patient payment, and travel and logistics support for top pharmaceutical and biotechnology companies. Learn more about our legacy at
More news about: Scout
Aug 12, 2025, 09:00 ET Catalyst Clinical Research Named to the 2025 Inc. 5000 List
Catalyst Clinical Research, a contract research organization (CRO), provides highly customizable solutions to the global biopharmaceutical and biotechnology industries through two established, branded solutions:
More news about: Catalyst Clinical Research
Aug 12, 2025, 09:00 ET Rezo Therapeutics Appoints Derek Hicks as CEO
Rezo Therapeutics, a biotechnology company pioneering the integrated mapping of disease networks for precision therapeutics, today announced that Derek Hicks
More news about: Rezo Therapeutics
Aug 12, 2025, 08:05 ET Anixa Biosciences Announces Issuance of Additional U.S. Patent for CAR-T Technology
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the United States Patent and Trademark Office (USPTO) has issued
More news about: Anixa Biosciences, Inc.